Nutriband

Q1 FY2027 EarningsQ1 FY26 revenue was $0.43M, down 35.06% YoY, primarily due to a major customer relocating operations to Asia and the wind-down of contracts in the 4P Therapeutics segment. Despite the revenue drop, net loss narrowed to $1.24M from $1.39M YoY, aided by a 63.82% reduction in R&D expenses. Cash position remained at $4.01M with working capital of $3.54M. The company continues to focus on AVERSA™ Fentanyl development with a remaining budget of $3.4M for NDA submission.